Clinical Trials
61 trialsNatural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
National Institutes of Health Clinical Center (CC)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
MK-1026-003
Merck Sharp & Dohme LLC
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Memorial Sloan Kettering Cancer Center
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
National Institutes of Health Clinical Center (CC)
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
M.D. Anderson Cancer Center
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
St. Jude Children's Research Hospital
HALTAging-1
University of Nebraska
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Dana-Farber Cancer Institute
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Cedars-Sinai Medical Center
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
APEX
Cogent Biosciences, Inc.
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
M.D. Anderson Cancer Center
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
DALY 2-EU
Miltenyi Biomedicine GmbH
PEACE
Massachusetts General Hospital
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Center for International Blood and Marrow Transplant Research
ADAPT-HEM
Beijing Biotech
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Aquarius
Tempus AI
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
University of Miami
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Children's Hospital Medical Center, Cincinnati
DISCOVERY
UNC Lineberger Comprehensive Cancer Center
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
St. Jude Children's Research Hospital
UHKT-CAR123-01
Institute of Hematology and Blood Transfusion, Czech Republic
Clinical Cohort of Lymphoma Patients in Malawi
UNC Lineberger Comprehensive Cancer Center
HEM-DOAC
Medical University of Gdansk
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Tele@home
Brno University Hospital
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HEME Home Transfusion Program
Dana-Farber Cancer Institute
HYCVA
Hospices Civils de Lyon
Cardio CAR-T
Assistance Publique - Hôpitaux de Paris
Mosaic
Northwestern University
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
AIDS Malignancy Consortium
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
University of Florida
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics, INC.
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
The Third Affiliated Hospital of Southern Medical University
BELUGA
Munich Leukemia Laboratory
SIRIUS
Munich Leukemia Laboratory
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium